➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

Details for Patent: 7,638,536

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,638,536 protect, and when does it expire?

Patent 7,638,536 protects DOPTELET and is included in one NDA.

This patent has twenty-one patent family members in fourteen countries.

Summary for Patent: 7,638,536
Title:2-Acylaminothiazole derivative or salt thereof
Abstract: A 2-acylaminothiazole derivative or a pharmaceutically acceptable salt thereof having an excellent effect of proliferating human c-mpl-Ba/F3 cells and an activity of increasing platelets based on the effect of promoting the formation of megakaryocytic colonies. A compound or a pharmaceutically acceptable salt thereof useful in treating thrombocytopenia.
Inventor(s): Sugasawa; Keizo (Tsukuba, JP), Watanuki; Susumu (Tsukuba, JP), Koga; Yuji (Tsukuba, JP), Nagata; Hiroshi (Tsukuba, JP), Obitsu; Kazuyoshi (Tsukuba, JP), Wakayama; Ryutaro (Tsukuba, JP), Hirayama; Fukushi (Tsukuba, JP), Suzuki; Ken-ichi (Tsukuba, JP)
Assignee: Astellas Pharma Inc. (Chuo-Ku, Tokyo, JP)
Application Number:10/500,964
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Dosage form;

Drugs Protected by US Patent 7,638,536

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Akarx Inc DOPTELET avatrombopag maleate TABLET;ORAL 210238-001 May 21, 2018 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,638,536

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2002-010413Jan 18, 2002
Japan2002-010447Jan 18, 2002
PCT Information
PCT FiledJanuary 15, 2003PCT Application Number:PCT/JP03/00270
PCT Publication Date:July 31, 2003PCT Publication Number: WO03/062233

International Family Members for US Patent 7,638,536

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2472711 ⤷  Free Forever Trial
China 1319967 ⤷  Free Forever Trial
China 1639157 ⤷  Free Forever Trial
Cyprus 1114169 ⤷  Free Forever Trial
Denmark 1466912 ⤷  Free Forever Trial
European Patent Office 1466912 ⤷  Free Forever Trial CA 2019 00057 Denmark ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.